$LQDA
Liquidia Corp

2021 Q4 Form 10-K Financial Statement

#000155837022003850 Filed on March 17, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $3.215M $12.85M $740.0K
YoY Change 334.46% 1637.81%
Cost Of Revenue $725.9K $3.023M $240.0K
YoY Change 202.47% 1171.67%
Gross Profit $2.489M $9.830M $500.0K
YoY Change 397.82% 1858.58%
Gross Profit Margin 77.42% 76.48% 67.57%
Selling, General & Admin $8.431M $17.74M $6.370M
YoY Change 32.36% 1.92% 10.02%
% of Gross Profit 338.73% 180.5% 1274.0%
Research & Development $5.381M $20.52M $5.250M
YoY Change 2.49% -36.33% -35.66%
% of Gross Profit 216.17% 208.71% 1050.0%
Depreciation & Amortization $871.6K $5.612M $950.0K
YoY Change -8.25% 79.32% 82.69%
% of Gross Profit 35.02% 57.09% 190.0%
Operating Expenses $13.85M $20.52M $11.61M
YoY Change 19.31% -36.33% -16.77%
Operating Profit -$11.36M -$33.80M -$11.11M
YoY Change 2.27% -42.8% -20.36%
Interest Expense -$200.7K $815.0K -$170.0K
YoY Change 18.05% -5.01% -68.52%
% of Operating Profit
Other Income/Expense, Net -$781.6K
YoY Change 16.03%
Pretax Income -$11.56M -$34.58M -$16.09M
YoY Change -28.13% -42.14% 11.04%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.56M -$34.58M -$16.09M
YoY Change -28.13% -42.14% 11.04%
Net Earnings / Revenue -359.66% -269.02% -2174.32%
Basic Earnings Per Share -$0.70
Diluted Earnings Per Share -$221.3K -$0.70 -$394.2K
COMMON SHARES
Basic Shares Outstanding 51.98M 49.68M
Diluted Shares Outstanding 49.68M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.49M $57.49M $65.32M
YoY Change -11.98% -11.98% 17.06%
Cash & Equivalents $57.49M $57.49M $65.30M
Short-Term Investments
Other Short-Term Assets $792.4K $792.4K $750.0K
YoY Change 5.65% 5.65% 27.12%
Inventory
Prepaid Expenses
Receivables $2.990M $2.990M $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $61.28M $61.28M $66.07M
YoY Change -7.25% -7.26% 17.17%
LONG-TERM ASSETS
Property, Plant & Equipment $5.017M $7.429M $6.806M
YoY Change -26.28% -21.38% -26.46%
Goodwill $3.903M $3.903M
YoY Change -0.01%
Intangibles $4.390M $5.535M
YoY Change -20.68%
Long-Term Investments
YoY Change
Other Assets $16.73M $16.73M $14.57M
YoY Change 14.83% 14.83% 3734.21%
Total Long-Term Assets $32.45M $32.45M $33.46M
YoY Change -3.02% -3.01% 168.66%
TOTAL ASSETS
Total Short-Term Assets $61.28M $61.28M $66.07M
Total Long-Term Assets $32.45M $32.45M $33.46M
Total Assets $93.73M $93.73M $99.53M
YoY Change -5.83% -5.83% 44.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.070M $1.070M $3.734M
YoY Change -71.35% -71.31% 6.75%
Accrued Expenses $5.946M $5.946M $5.310M
YoY Change 11.97% 11.97% -18.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $311.0K $311.0K $0.00
YoY Change -66.2% -100.0%
Total Short-Term Liabilities $7.327M $7.327M $11.74M
YoY Change -37.58% -37.59% -30.44%
LONG-TERM LIABILITIES
Long-Term Debt $10.41M $10.76M $10.29M
YoY Change 1.14% 2.01% 0.0%
Other Long-Term Liabilities $10.38M $10.38M $6.160M
YoY Change 68.43% 68.43% 8.64%
Total Long-Term Liabilities $10.41M $21.14M $10.29M
YoY Change 1.14% 26.49% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.327M $7.327M $11.74M
Total Long-Term Liabilities $10.41M $21.14M $10.29M
Total Liabilities $28.46M $28.46M $28.45M
YoY Change 0.06% 0.05% -16.08%
SHAREHOLDERS EQUITY
Retained Earnings -$309.6M -$275.0M
YoY Change 12.57% 27.77%
Common Stock $52.00K $43.34K
YoY Change 19.99% 53.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.27M $65.27M $71.09M
YoY Change
Total Liabilities & Shareholders Equity $93.73M $93.73M $99.53M
YoY Change -5.83% -5.83% 44.58%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$11.56M -$34.58M -$16.09M
YoY Change -28.13% -42.14% 11.04%
Depreciation, Depletion And Amortization $871.6K $5.612M $950.0K
YoY Change -8.25% 79.32% 82.69%
Cash From Operating Activities -$7.559M -$34.04M -$14.08M
YoY Change -46.31% -37.14% 0.14%
INVESTING ACTIVITIES
Capital Expenditures -$19.98K $107.2K -$40.00K
YoY Change -50.05% -85.74% -69.23%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $1.000M
YoY Change -100.0% -100.0%
Cash From Investing Activities -$19.98K -$107.2K $960.0K
YoY Change -102.08% -143.25% -838.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $10.35M
YoY Change 83.33%
Cash From Financing Activities 1.019M 26.32M -1.100M
YoY Change -192.68% -58.5% -103.59%
NET CHANGE
Cash From Operating Activities -7.559M -34.04M -14.08M
Cash From Investing Activities -19.98K -107.2K 960.0K
Cash From Financing Activities 1.019M 26.32M -1.100M
Net Change In Cash -6.560M -7.823M -14.22M
YoY Change -53.87% -182.17% -186.23%
FREE CASH FLOW
Cash From Operating Activities -$7.559M -$34.04M -$14.08M
Capital Expenditures -$19.98K $107.2K -$40.00K
Free Cash Flow -$7.539M -$34.14M -$14.04M
YoY Change -46.3% -37.81% 0.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49678647
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33888434
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001819576
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43336277
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52287737
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.76
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39724
CY2021 dei Entity Registrant Name
EntityRegistrantName
LIQUIDIA CORPORATION
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1710962
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
419 Davis Drive, Suite 100
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Morrisville
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27560
CY2021 dei City Area Code
CityAreaCode
919
CY2021 dei Local Phone Number
LocalPhoneNumber
328-4400
CY2021 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
LQDA
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5006301
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
351714
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
255402
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10409950
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10292485
CY2021Q4 us-gaap Liabilities
Liabilities
28463678
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
61668021
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52435802
CY2021 dei Auditor Firm
AuditorFirmId
238
CY2021 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2021 dei Auditor Location
AuditorLocation
Raleigh, North Carolina
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57493933
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65316481
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2989717
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
792381
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
752447
CY2021Q4 us-gaap Assets Current
AssetsCurrent
61276031
CY2020Q4 us-gaap Assets Current
AssetsCurrent
66068928
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5017394
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6805570
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2412025
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2649328
CY2021Q4 lqda Indemnification Asset Related Party
IndemnificationAssetRelatedParty
6281874
CY2020Q4 lqda Indemnification Asset Related Party
IndemnificationAssetRelatedParty
1387275
CY2021Q4 lqda Business Combination Contract Acquisition Costs Net
BusinessCombinationContractAcquisitionCostsNet
10138434
CY2020Q4 lqda Business Combination Contract Acquisition Costs Net
BusinessCombinationContractAcquisitionCostsNet
12792491
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4389676
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5534843
CY2021Q4 us-gaap Goodwill
Goodwill
3903282
CY2020Q4 us-gaap Goodwill
Goodwill
3903282
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
310503
CY2020Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
390043
CY2021Q4 us-gaap Assets
Assets
93729219
CY2020Q4 us-gaap Assets
Assets
99531760
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1069982
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3734227
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3156787
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3259515
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2014487
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1386880
CY2020Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
1768864
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
774590
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
664670
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
310949
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
923218
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7326795
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11737374
CY2021Q4 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
6143508
CY2020Q4 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
1154360
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4231711
CY2020Q4 us-gaap Liabilities
Liabilities
28445922
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52287737
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43336277
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
52288
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
43336
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
374794120
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
346044721
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309580867
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275002219
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65265541
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
71085838
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93729219
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99531760
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12853345
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
739628
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3022911
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
237712
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20516948
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32222393
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23110529
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27368653
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
46650388
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
59828758
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-33797043
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-59089130
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
33435
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
184359
CY2021 us-gaap Interest Expense
InterestExpense
815040
CY2020 us-gaap Interest Expense
InterestExpense
857998
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-781605
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-673639
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34578648
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-59762769
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.76
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49677737
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33888434
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
34947547
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67916
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
19415
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71016398
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
20843331
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3954000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-59762769
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
71085838
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41075
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21709949
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
261000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6746327
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34578648
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65265541
CY2021 us-gaap Profit Loss
ProfitLoss
-34578648
CY2020 us-gaap Profit Loss
ProfitLoss
-59762769
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6746327
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3954000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5611879
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3129579
CY2021 lqda Noncash Portion Of Lease Expense
NoncashPortionOfLeaseExpense
237303
CY2020 lqda Noncash Portion Of Lease Expense
NoncashPortionOfLeaseExpense
174102
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-43954
CY2020 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-10802
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
284969
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
61424
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2989717
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
0
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
39934
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
132007
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-79540
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
12000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7558844
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-297160
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-102728
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
42312
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
663774
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
180736
CY2021 lqda Increase Decrease In Refund Liability
IncreaseDecreaseInRefundLiability
-1768864
CY2020 lqda Increase Decrease In Refund Liability
IncreaseDecreaseInRefundLiability
-927136
CY2021 lqda Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-664670
CY2020 lqda Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-566390
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34035659
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54144507
CY2021 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1000000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
107220
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
752086
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-107220
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
247914
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
477170
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1122356
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10352940
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5647060
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10410269
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2021 us-gaap Loss Contingency Receivable Proceeds
LossContingencyReceivableProceeds
4989148
CY2020 us-gaap Loss Contingency Receivable Proceeds
LossContingencyReceivableProceeds
507849
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
21709949
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
71225398
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1634467
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
41075
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
87332
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26320331
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63416696
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7822548
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9520103
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65316481
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55796378
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57493933
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65316481
CY2021 us-gaap Interest Paid Net
InterestPaidNet
423230
CY2020 us-gaap Interest Paid Net
InterestPaidNet
820889
CY2021 lqda Operating Lease Liabilities Cash Paid
OperatingLeaseLiabilitiesCashPaid
1207708
CY2020 lqda Operating Lease Liabilities Cash Paid
OperatingLeaseLiabilitiesCashPaid
1172759
CY2021 lqda Reduction Of Lease Liability And Right Of Use Asset From Lease Modification
ReductionOfLeaseLiabilityAndRightOfUseAssetFromLeaseModification
38787
CY2020 lqda Reduction Of Lease Liability And Right Of Use Asset From Lease Modification
ReductionOfLeaseLiabilityAndRightOfUseAssetFromLeaseModification
0
CY2021 lqda Increase In Indemnification Asset Through Accounts Payable
IncreaseInIndemnificationAssetThroughAccountsPayable
4894599
CY2020 lqda Increase In Indemnification Asset Through Accounts Payable
IncreaseInIndemnificationAssetThroughAccountsPayable
321737
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
412096
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Liquidia Corporation (“Liquidia” or the “Company”) is a biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary hypertension (“PH”). Liquidia Corporation operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. (“Liquidia Technologies”) and Liquidia PAH, LLC (“Liquidia PAH”), formerly known as RareGen, LLC (“RareGen”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company generates revenue primarily pursuant to a promotion agreement between Liquidia PAH and Sandoz Inc. (“Sandoz”), dated as of August 1, 2018, as amended (the “Promotion Agreement”), sharing profit derived from the sale of the first-to-file fully substitutable generic treprostinil injection (“Treprostinil Injection”) in the United States. Liquidia PAH has the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection. The Company employs a targeted sales force calling on physicians and hospital pharmacies involved in the treatment of pulmonary arterial hypertension (“PAH”) in the United States, as well as key stakeholders involved in the distribution and reimbursement of Treprostinil Injection. Strategically, the Company believes that its commercial presence in the field will enable an efficient base to expand from for the launch of YUTREPIA upon final approval, leveraging existing relationships and further validating its reputation as a company committed to supporting PAH patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company conducts research, development and manufacturing of novel products by applying its proprietary PRINT® technology, a particle engineering platform, to enable precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s lead product candidate, for which it holds worldwide commercial rights, is YUTREPIA for the treatment of PAH. YUTREPIA is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep lung delivery and achieving higher dose levels than current inhaled therapies. The Company’s New Drug Application (“NDA”) for YUTREPIA was tentatively approved by the Food and Drug Administration (“FDA”) in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the impact of the COVID-19 coronavirus, and the ability to secure additional capital to fund operations. The Company expects to incur significant expenses and operating losses for the foreseeable future as it seeks regulatory approval and pursues commercialization of any approved product candidates. In addition, if the Company obtains marketing approval for any of its current or future product candidates, it would incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if the Company's development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company is not able to generate significant revenues from the sale of YUTREPIA it will likely be required to raise additional funds through debt, equity or other forms of financing, such as potential collaboration arrangements. If the Company determines it requires but is unable to obtain funding, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.</p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57500000
CY2021Q4 lqda Debt Instrument Minimum Cash Covenant
DebtInstrumentMinimumCashCovenant
27500000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known. Actual results will most likely differ from those estimates.</p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57500000
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
56500000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65300000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;margin:0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheet. 100% of the Company’s cash and cash equivalents are held with Silicon Valley Bank (“SVB”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, one customer accounted for 99% of revenue. As of December 31, 2021, one customer accounted for 98% of the Company's accounts receivable.</p>
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5663054
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2751230
CY2021Q4 lqda Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
90000000
CY2021Q4 lqda Common Stock And Preferred Stock Par Or Stated Value Per Share
CommonStockAndPreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6746327
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3954000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6746327
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3954000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0062
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0167
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0040
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0160
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.91
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.96
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.87
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.94
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.23
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.78
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4692071
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.51
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2023950
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.72
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14758
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.85
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1103254
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.10
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5598009
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.19
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8761969
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3131403
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.76
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4348315
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5579988
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.18
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8747263
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5598009
CY2021 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3131403
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
21361
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
176433
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6169000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4178659
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14758
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
91413
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41075
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43141
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18600465
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19783740
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13583071
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12978170
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5017394
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6805570
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1812655
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2856914
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2856914
CY2021 us-gaap Cost Of Property Repairs And Maintenance
CostOfPropertyRepairsAndMaintenance
110608
CY2020 us-gaap Cost Of Property Repairs And Maintenance
CostOfPropertyRepairsAndMaintenance
194192
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
57301955
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
54844147
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4203773
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3995782
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3213345
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1501172
CY2021Q4 lqda Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1626744
CY2020Q4 lqda Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1576326
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
799448
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
193490
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
249998
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
17421
CY2021Q4 lqda Deferred Tax Assets Refund Liability
DeferredTaxAssetsRefundLiability
0
CY2020Q4 lqda Deferred Tax Assets Refund Liability
DeferredTaxAssetsRefundLiability
620442
CY2021Q4 lqda Deferred Tax Assets Patent Amortization
DeferredTaxAssetsPatentAmortization
324786
CY2020Q4 lqda Deferred Tax Assets Patent Amortization
DeferredTaxAssetsPatentAmortization
76017
CY2021Q4 lqda Deferred Tax Assets Accrued Litigation Costs
DeferredTaxAssetsAccruedLitigationCosts
1641583
CY2020Q4 lqda Deferred Tax Assets Accrued Litigation Costs
DeferredTaxAssetsAccruedLitigationCosts
265659
CY2021Q4 lqda Deferred Tax Assets Settlement Reserve
DeferredTaxAssetsSettlementReserve
140682
CY2020Q4 lqda Deferred Tax Assets Settlement Reserve
DeferredTaxAssetsSettlementReserve
0
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1763
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1763
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
66986990
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
61595499
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2517087
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1496720
CY2021Q4 lqda Deferred Tax Liabilities Adjustments Due To Changes In Accounting Methods
DeferredTaxLiabilitiesAdjustmentsDueToChangesInAccountingMethods
48317
CY2020Q4 lqda Deferred Tax Liabilities Adjustments Due To Changes In Accounting Methods
DeferredTaxLiabilitiesAdjustmentsDueToChangesInAccountingMethods
62420
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1678555
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
675866
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
790215
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
758434
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2517087
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1496720
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5391500
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7261318
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12550174
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2625563
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.076
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1203286
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.02
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
2929
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
286226
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
247011
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.004
CY2021 lqda Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
0
CY2021 lqda Effective Income Tax Rate Reconciliation Transaction Costs Percent
EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
0
CY2020 lqda Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
573494
CY2020 lqda Effective Income Tax Rate Reconciliation Transaction Costs Percent
EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
-0.010
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
261735
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.008
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
978793
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.016
CY2021 us-gaap Income Tax Reconciliation Tax Settlements State And Local
IncomeTaxReconciliationTaxSettlementsStateAndLocal
4454297
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
-0.129
CY2020 us-gaap Income Tax Reconciliation Tax Settlements State And Local
IncomeTaxReconciliationTaxSettlementsStateAndLocal
-667
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
0
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
16602
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-70721
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5391491
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.156
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13980207
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.233
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
158710
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
244698
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
403408
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
51999
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
455407
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021Q4 lqda North Carolina Corporate Income Tax Rate
NorthCarolinaCorporateIncomeTaxRate
0.025
CY2021Q4 lqda North Carolina Corporate Income Tax Rate Expected
NorthCarolinaCorporateIncomeTaxRateExpected
0
CY2021 lqda Income Tax Expense Due To Reduction In North Carolina Deferred Tax Assets
IncomeTaxExpenseDueToReductionInNorthCarolinaDeferredTaxAssets
5100000
CY2021Q1 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.075
CY2021Q1 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.065
CY2021 us-gaap Lease Cost
LeaseCost
1090031
CY2020 us-gaap Lease Cost
LeaseCost
2262436
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2021Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.103
CY2021Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.065
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1243934
CY2021Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
342762
CY2021Q4 lqda Lease Liability Payments Due Next Twelve Months
LeaseLiabilityPaymentsDueNextTwelveMonths
1586696
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1283253
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
195350
CY2021Q4 lqda Lease Liability Payments Due Year Two
LeaseLiabilityPaymentsDueYearTwo
1478603
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1316540
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
114727
CY2021Q4 lqda Lease Liability Payments Due Year Three
LeaseLiabilityPaymentsDueYearThree
1431267
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1355923
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
64161
CY2021Q4 lqda Lease Liability Payments Due Year Four
LeaseLiabilityPaymentsDueYearFour
1420084
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1157807
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2021Q4 lqda Lease Liability Payments Due Year Five
LeaseLiabilityPaymentsDueYearFive
1157807
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6357457
CY2021Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
717000
CY2021Q4 lqda Lease Liability Payments Due Total
LeaseLiabilityPaymentsDueTotal
7074457
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1351156
CY2021Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
54337
CY2021Q4 lqda Lease Liability Undiscounted Excess Amount
LeaseLiabilityUndiscountedExcessAmount
1405493
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5006301
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
662663
CY2021Q4 lqda Lease Liability
LeaseLiability
5668964
CY2021 lqda Maximum Net Sales Threshold As Basis For Payment Of Future Contingent Royalties
MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties
1500000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10409950
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10292485
CY2021Q1 lqda Number Of Subsidiaries
NumberOfSubsidiaries
2
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
321804
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
416345

Files In Submission

Name View Source Status
0001558370-22-003850-index-headers.html Edgar Link pending
0001558370-22-003850-index.html Edgar Link pending
0001558370-22-003850.txt Edgar Link pending
0001558370-22-003850-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lqda-20211231.xsd Edgar Link pending
lqda-20211231x10k.htm Edgar Link pending
lqda-20211231x10k001.jpg Edgar Link pending
lqda-20211231x10k_htm.xml Edgar Link completed
lqda-20211231xex10d36.htm Edgar Link pending
lqda-20211231xex10d44.htm Edgar Link pending
lqda-20211231xex10d45.htm Edgar Link pending
lqda-20211231xex21d1.htm Edgar Link pending
lqda-20211231xex23d1.htm Edgar Link pending
lqda-20211231xex31d1.htm Edgar Link pending
lqda-20211231xex31d2.htm Edgar Link pending
lqda-20211231xex32d1.htm Edgar Link pending
lqda-20211231xex32d2.htm Edgar Link pending
lqda-20211231_cal.xml Edgar Link unprocessable
lqda-20211231_def.xml Edgar Link unprocessable
lqda-20211231_lab.xml Edgar Link unprocessable
lqda-20211231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending